A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context

Health Technology Assessment

Volumn 10, Issue 27, 2006, Pages 1-132

  Buxton, M ^a   Caine, N ^b   Chase, D ^c   Connelly, D ^d   Grace, A ^e   Jackson, C ^f   Parkes, J ^g   Sharples, L ^h  

^a BRUNEL UNIVERSITY   (United Kingdom)

^b Department of Health ^*  (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d GLASGOW ROYAL INFIRMARY   (United Kingdom)

^e PAPWORTH HOSPITAL   (United Kingdom)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL; PROPAFENONE; SOTALOL;

AGE DISTRIBUTION; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEFIBRILLATOR; DEMOGRAPHY; DISEASE EXACERBATION; DRUG FATALITY; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; FUNCTIONAL ASSESSMENT; GENDER BIAS; HEALTH CARE COST; HEALTH ECONOMICS; HEART ARRHYTHMIA; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL ANXIETY AND DEPRESSION SCALE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPERTHYROIDISM; ISCHEMIC HEART DISEASE; LIVER TOXICITY; LUNG TOXICITY; META ANALYSIS; PATIENT SATISFACTION; POSTAL MAIL; PRIMARY PREVENTION; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RESOURCE MANAGEMENT; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; SHORT FORM 36; SUDDEN DEATH; SURVIVAL RATE; SYNCOPE; SYSTEMATIC REVIEW; THYROID DISEASE; UNITED KINGDOM;

AGED; ARRHYTHMIA; ARRHYTHMIAS, CARDIAC; COST-BENEFIT ANALYSIS; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; GREAT BRITAIN; HOSPITALIZATION; HUMANS; MALE; MARKOV CHAINS; PATIENT SELECTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 33749663442     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. National Institute for Clinical Excellence. Guidance on the use of implantable cardioverter defibrillators for arrhythmias. Technology Appraisal Guidance No. 11. London: NICE; 2000.
2. Parkes J, Bryant J, Milne R. Implantable cardioverter defibrillators: arrhythmias. A rapid and systematic review. Health Technol Assess 2000;4(26).
3. Alexander M, Baker L, Clark C, McDonald KM, Rowell R, Saynina O, et al. Management of ventricular arrhythmias in diverse populations in California. Am Heart J 2002;144:431-9.
4. Becker LB, Smith DW, Rhodes KV. Incidence of cardiac arrest: a neglected factor in evaluating survival rates. Ann Emerg Med 1993;22:86-91.
5. Cobb LA, Fahrenbruch CE, Olsufka M, Copass MK. Changing incidence of out-of-hospital ventricular fibrillation, 1980-2000. JAMA 2002;288:3008-13.
6. Sedgwick ML, Dalziel K, Watson J, Carrington DJ, Cobbe SM. Performance of an established system of first responder out-of-hospital defibrillation. The results of the second year of the Heartstart Scotland Project in the 'Utstein Style'. Resuscitation 2000; 26:75-88.
7. Priori SG, Aliot E, Blomstrom-Lundqvist C, Bossaert L, Breithardt G, Brugada P, et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001; 22:1374-450.
8. Priori SG, Aliot E, Blomstrom-Lundquist C, Bossaert L, Breithardt G, Brugada P, et al., Update of the guidelines on sudden cardiac death of the European Society of Cardiology. Eur Heart J 2003; 24:13-15.
9. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001;104:2158-63.
10. Capewell S, MacIntyre K, Stewart S, Chalmers JW, Boyd J, Finlayson A, et al. Age, sex, and social trends in out-of-hospital cardiac deaths in Scotland 1986-95: a retrospective cohort study. Lancet 2001; 358:1213-17.
11. Cobb LA, Baum RS, Alvarez H III, Schaffer WA. Resuscitation from out-of-hospital ventricular fibrillation: 4 years follow-up. Circulation 1975; 52(6 Suppl):III223-35.
12. Fox CS, Evans JC, Larson MG, Kannel WB, Levy D. Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950 to 1999. Circulation 2004;110:522-7.
13. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335:1933-40.
14. Buxton AE, Fisher JD, Josephson ME, Lee KL, Pryor DB, Prystowsky EN, et al. Prevention of sudden death in patients with coronary artery disease: the Multicenter Unsustained Tachycardia Trial (MUSTT). Prog Cardiovasc Dis 1993;36:215-26.
15. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. Multicenter Unsustained Tachycardia Trial Investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999; 341:1882-90.
16. Bigger JT Jr. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med 1997; 337:1569-75.
17. Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337:1576-83.
18. Sibels J, Cappato R, Ruppel R, Schneider MA, Kuck KH. CASH Investigators. Preliminary results of the Cardiac Arrest Study Hamburg (CASH). Am J Cardiol 1993;72:109-13F.
19. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000;101:1297-302.
20. Wever EF, Hauer RN, van Capelle FL, Tijssen JG, Crijns HJ, Algra A, et al. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. Circulation 1995;91:2195-203.
21. Connolly SJ, Gent M, Roberts RS, Dorian P, Green MS, Klein GJ, et al. CIDS Co-Investigators. Canadian Implantable Defibrillator Study (CIDS): study design and organization. Am J Cardiol 1993; 72:103-8F.
22. Namerow PB, Firth BR, Heywood GM, Windle JR, Parides MK. Quality-of-life six months after CABG surgery in patients randomized to ICD versus no ICD therapy: findings from the CABG Patch Trial. Pacing Clin Electrophysiol 1999;22:1305-13.
23. Brooks MM, Jenkins LS, Schron EB, Steinberg JS, Cross JA, Paeth DS. AVID Investigators. The Antiarrhythmics Versus Implantable Defibrillators. Quality of life at baseline: is assessment after randomization valid? Med Care 1998;36:1515-19.
24. Sears SF Jr, Todaro JF, Lewis TS, Sotile W, Conti JB. Examining the psychosocial impact of implantable cardioverter defibrillators: a literature review. Clin Cardiol 1999;22:481-9.
25. Hegel MT, Griegel LE, Black C, Goulden L, Ozahowski T. Anxiety and depression in patients receiving implanted cardioverter-defibrillators: a longitudinal investigation. Int J Psychiatry Med 1997;27:57-69.
26. Herrmann C, von zur Muhen F, Schaumann A, Buss U, Kemper S, Wantzen C, et al. Standardized assessment of psychological well-being and quality-of-life in patients with implanted defibrillators. Pacing Clin Electrophysiol 1997;20:95-103.
27. NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD guidelines for those carrying out or commissioning reviews. York: CRD; 1999.
28. Sackett D. Undertaking systematic reviews of research on effectiveness. York: CRD; 2000.
29. Bryant J, Brodin H, Loveman E, Payne E, Clegg A. The clinical and cost-effectiveness of implantable cardioverter defibrillators: a systematic review. Health Technol Assess 2005;9(36).
30. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator Study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 2000; 21:2071-8.
31. Office for National Statistics. Labour force survey 2000. London: ONS; 2000.
32. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102:748-54.
33. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346:877-83.
34. Bansch D, Antz M, Boczor S, Volkmer M, Tebbenjohanns J, Seidl K, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 2002;105:1453-8.
35. Irvine J, Dorian P, Baker B, O'Brien BJ, Roberts R, Gent M, et al. Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am Heart J 2002;144:282-9.
36. Schron EB, Exner DV, Yao Q, Jenkins LS, Steinberg JS, Cook JR, et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 2002;105:589-94.
37. Ezekowitz JA, Armstrong PW, McAlister FA. Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. Ann Intern Med 2003; 138:445-52.
38. The collection and analysis of quality of life data in MADIT and MADIT II. Quality of life in arrhythmic trials session. 20th Annual Scientific Sessions of the North American Society of Pacing and Electrophysiology, Toronto, Canada; 1999.
39. Exner DV. Quality of life in patients with life-threatening arrhythmias: does choice of therapy make a difference? Am HeartJ 2002;144:208-11.
40. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993; 270:1589-95.
41. Heidenreich PA, Keeffe B, McDonald KM, Hlatky MA. Overview of randomized trials of antiarrhythmic drugs and devices for the prevention of sudden cardiac death. Am Heart J 2002;144:422-30.
42. Hlatky MA, Saynina O, McDonald KM, Garber AM, McClellan MB. Utilization and outcomes of the implantable cardioverter defibrillator, 1987 to 1995. Am Heart J 2002;144:397-403.
43. McDonald KM, Hlatky MA, Saynina O, Geppert J, Garber AM, McClellan MB. Trends in hospital treatment of ventricular arrhythmias among Medicare beneficiaries, 1985 to 1995. Am Heart J 2002;144:413-21.
44. Bigger JT. Expanding indications for implantable cardiac defibrillators. N Engl J Med 2002;346:931-3.
45. Kuppermann M, Luce BR, McGovern B, Podrid PJ, Bigger JT Jr, Ruskin JN. An analysis of the cost effectiveness of the implantable defibrillator. Circulation 1990;81:91-100.
46. O'Brien BJ, Buxton MJ, Rusbby JA. Cost effectiveness of the implantable cardioverter defibrillator: a preliminary analysis. Br Heart J 1992;68:241-5.
47. Larsen GC, Manolis AS, Sonnenberg FA, Beshansky JR, Estes NA, Pauker SG. Cost-effectiveness of the implantable cardioverter-defibrillator: effect of improved battery life and comparison with amiodarone therapy. J Am Coll Cardiol 1992;19:1323-34.
48. Kupersmith J, Hogan A, Guerrero P, Gardiner J, Mellits ED, Baumgardner R, et al. Evaluating and improving the cost-effectiveness of the implantable cardioverter-defibrillator. Am Heart J 1995; 130:507-15.
49. Wever EF, Hauer RN, Schrijvers G, van Capelle FJ, Tijssen JG, Crijns HJ, et al. Cost-effectiveness of implantable defibrillator as first-choice therapy versus electrophysiologically guided, tiered strategy in postinfarct sudden death survivors. A randomized study. Circulation 1996;93:489-96.
50. Owens DK, Sanders GD, Harris RA, McDonald KM, Heidenreich PA, Dembitzer AD, et al. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. Ann Intern Med 1997; 126:1-12.
51. O'Brien BJ, Connolly SJ, Goeree R, Blackhouse G, Willan A, Yee R, et al. Cost-effectiveness of the implantable cardioverter-defibrillator: results from the Canadian Implantable Defibrillator Study (CIDS). Circulation 2001;103:1416-21.
52. Sheldon R, O'Brien BJ, Blackhouse G, Goeree R, Mitchell B, Klein G, et al. Effect of clinical risk stratification on cost-effectiveness of the implantable cardioverter-defibrillator: the Canadian implantable defibrillator study. Circulation 2001; 104:1622-6.
53. Larsen G, Hallstrom A, McAnulty J, Pinski S, Olarte A, Sullivan S, et al. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias: results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis substudy. Circulation 2002;105:2049-57.
54. Weiss JP, Saynina O, McDonald KM, McClellan MB, Hlatky MA. Effectiveness and cost-effectiveness of implantable cardioverter defibrillators in the treatment of ventricular arrhythmias among Medicare beneficiaries. Am J Med 2002;112:519-27.
55. Mushlin AI, Hall WJ, Zwanziger J, Gajary E, Andrews M, Marron R, et al. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. Circulation 1998; 97:2129-35.
56. Sanders GD, Hlatky MA, Every NR, McDonald KM, Heidenreich PA, Parsons LS, et al. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Ann Intern Med 2001; 135:870-83.
57. Owens DK, Sanders GD, Heidenreich PA, McDonald KM, Hlatky MA. Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. Am Heart J 2002;144:440-8.
58. Curtis L, Netten A. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit; 2002.
59. Cummins C, Winter H, Cheng KK, Maric R, Silcocks P, Varghese C. An assessment of the Nam Pehchan computer program for the identification of names of south Asian ethnic origin. J Public Health Med 1999;21:401-6.
60. Plummer CJ, McComb JM. An audit of the implications of implementing NICE guidance on the use of implantable cardioverter-defibrillators. Heart 2003;89:787-8.
61. Rubin DB, Schenker N. Multiple imputation for interval estimation from simple random samples with ignorable nonresponse. Journal of the American Statistical Association 1986;81:366-74.
62. Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley; 1987.
63. Rubin DB, Schenker N. Multiple imputation in health-care databases: an overview and some applications. Stat Med 1991;10:585-98.
64. Ware JE Jr, Gandek B, Kosinski M, Aaronson NK, Apolone G, Brazier J, et al. The equivalence of SF36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA project. International Quality of Life Assessment. J Clin Epidemiol 1998; 51:1167-70.
65. Kind P. The EuroQol instrument: an index of health-related quality of life. Philadelphia, PA: Lippincott-Raven; 1996.
66. Dolan P, Gudex C, Kind P, Williams A. A social tariff for Euroqol: results from a UK general population survey. Discussion Paper 138. York: Centre for Health Economics 1995.
67. Burke JL, Hallas CN, Clark-Carter D, White D, Connelly D. The psychosocial impact of the implantable cardioverter defibrillator: a meta-analytic review. Br J Health Psychol 2003;8:165-78.
68. Kohn CS, Petrucci RJ, Baessler C, Soto DM, Movsowitz C. The effect of psychological intervention on patients' long-term adjustment to the ICD: a prospective study. Pacing Clin Electrophysiol 2000;23:450-6.
69. Pauli P, Wiedemann G, Dengler W, Blaumann-Benninghoff G, Kuhlkamp V. Anxiety in patients with an automatic implantable cardioverter defibrillator: what differentiates them from panic patients? Psychosom Med 1999;61:69-76.
70. Cox DR, Miller HD. The theory of stochastic processes. London: Chapman & Hall; 1965.
71. HM Treasury. Green Book, Appraisal and Evaluation in Central Government, 2003. http://www.hm-treasury.gov.uk/Economic_Data_and_Tools/Greenbook/ datae_greenbook_index.cfm
72. West P. A clinical and economic evaluation on the use of implantable cardioverter defibrillators for ventricular tachyarrhythmias. York Health Economics Consortium, University of York; 2001.
73. Huikuri HV, Makikallio TH, Raatikainen MJ, Perkiomaki J, Castellanos A, Myerburg RJ. Prediction of sudden cardiac death: appraisal of the studies and methods assessing the risk of sudden arrhythmic death. Circulation 2003;108:110-15.
74. Saumarez RC, Chojnowska L, Derksen R, Pytkowski M, Sterlinski M, Huang CL, et al. Sudden death in noncoronary heart disease is associated with delayed paced ventricular activation. Circulation 2003;107:2595-600.
75. Assman SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000;355:1064-9.
76. Pocock SJ, Assman SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med 2002;21:2917-30.
77. Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL, et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT. J Am Coll Cardiol 2003;41: 1707-12.
78. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-50.
79. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004;350:2151-8.
80. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004; 351:2481-8.
81. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37.
82. Desai AS, Fang JC, Maisel WH, Baughmann KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy. A meta-analysis of randomized controlled trials. JAMA 2004;292:2874-9.
83. Nanthakumar K, Epstein AE, Kay GN, Plumb VJ, Lee DS. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction. J Am Coll Cardial 2004; 44:2166-72.
84. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005;353:1471-80.